Bufezolac

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C21H22N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PUA774J9MP, chemically known as 1-isobutyl-3,4-diphenylpyrazole-5-acetic acid but generally known as bufezolac, which bears US NIH Compound Identifier 68676. European Medicines Agency schedules Bufezolac in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05962MIG. The term BUFEZOLAC is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). BUFEZOLAC is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bufezolac under HS 29331990 and SITC 51571. As of Q4 2014, BUFEZOLAC remains the US FDA Preferred Term for this commodity. Bufezolac bears US NLM identifiers UMLS ID C2347228 and NCI Concept Code C73081. SMILES: OC(=O)CC1N(NC(C1C1CCCCC1)C1CCCCC1)CC(C)C.